Theranostics and how it works

Theranostics is a treatment using diagnostic imaging to identify if target receptors are present on cancer cells, followed by precision radiation treatment that target these receptors.

Make an enquiry

Theranostics

Make an enquiry about theranostics

Contact our theranostics team directly to find out how we can help you.

Theranostics can be used to treat cancers that have spread (metastasised), or where cancer is advanced and/or hasn’t responded to other treatments.

While in the future theranostics may be used for different cancers, to date most experience and success has been in metastatic prostate cancer and neuroendocrine tumours.

Metastatic prostate cancer

/content/dam/asset-migration/graphics/au/AU_Oncology_Metastatic_prostate_cancer_Graphic_GA.jpeg

How it works

Theranostics is a personalised approach to treating cancer, using both diagnosis and therapy tools as part of the treatment. Theranostics uses PET scan imaging (a special type of scan) to see if specific targets, known as tumour receptors, are present on tumour cells.

If these targets are present and visible on the scan, a radioactive drug is used to treat the tumours. The drug is given as an injection and selectively targets the tumour cells while avoiding healthy areas. Most of the radioactive drug that doesn’t reach the target is quickly passed out of the body.

/content/dam/asset-migration/graphics/au/AU_Oncology_Theranostics_Graphic_GA.jpeg

Limited clinical trial evidence is available for the use of theranostics in prostate cancer and the treatment has not yet been reviewed by the Australian Medicines Regulator – The Therapeutic Goods Administration (TGA).

Access to treatment is authorised via the TGA Special Access Scheme, a scheme for compassionate access to medicines before registration. It is an out of pocket expense for patients as theranostics is not currently covered by Medicare or private health insurance.

Treatment for advanced prostate cancer

Lutetium-177 PSMA therapy (Lu-PSMA) is a new treatment for advanced prostate cancer. It delivers high doses of targeted radiation to the cancer sites. It’s used to specifically target the abnormal cells while limiting damage to surrounding healthy tissue.

Lutetium PSMA therapy at GenesisCare

Find out more on lutetium PSMA therapy including how it works and who it's for.

Treatment for advanced neuroendocrine tumours

Lutetium-177 Octreotate therapy (Lu-Octreotate) is a treatment for advanced neuroendocrine tumours (NETs) or carcinoids.

It delivers high doses of targeted radiation to the cancer sites. It’s used to specifically target the abnormal cells while limiting damage to surrounding healthy tissue. This therapy has been used for almost 20 years in this tumour type and is now approved for the treatment of progressive advanced neuroendocrine tumours in Europe and the USA.

Lutetium octreotate therapy at GenesisCare

Find out more on lutetium octreotate therapy including how it works and who it's for.

Theranostics patient journey

It is important that you feel informed and supported on your Theranostics treatment journey. We are here to answer any questions or concerns you may have. Here are questions that others often ask:

Where is theranostics offered?

We currently have five centres in Australia offering theranostics treatment for our patients.

Make an enquiry about theranostics

Contact our theranostics team directly to find out how we can help you.

Our partnerships

For enquiries regarding partnership opportunities, please contact us via theranosticsreception@genesiscare.com.au

Publications

Title Author/s Journal & Date
Combining External Beam Radiation and Radionuclide Therapies: Rationale, Radiobiology, Results and Roadblocks Abbott EM et al. Clinical Oncology, https://doi.org/10.1016/j.clon.2021.09.004
Recurrent Prostate Cancer Lenzo N, Sohi J.S, Lim T.S. Appl Radiol 2021; Jul/Aug:40-43.
Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial Koschel S, Taubman K, Sutherland T, Yap K, Chao M, Guerrieri M, Benson A, Starmans M, Byrne G, Ong G, Macleod C, Foo M, Wong LM, Gyomber D, Ng M. April 2021
Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients Kesavan M, Meyrick D, Gallyamov M, Turner JH, Yeo S, Cardaci G, Lenzo NP. March 2021
Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer Meyrick D, Gallyamov M, Sabarimurugan S, Falzone N, Lenzo N. March 2021
Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer Asokendaran ME, Meyrick DP, Skelly LA, Lenzo NP, Henderson A. August 2019
Renal outcomes of radioligand therapy: experience of 177lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer Gallyamov M, Meyrick D, Barley J, Lenzo N. August 2019
177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer by Eyben FE, Singh A, Zhang J, Nipsch K, Meyrick D, Lenzo N, Kairemo K, Joensuu T, Virgolini I, Soydal C, Kulkarni HR, Baum RP. March 2019

Our theranostic specialists

A/Prof David Macfarlane

MB BS (Hons, Qld), FRACP, FAANMS

Nuclear Medicine Physician

Hurstville (Oncology) +1

Prof Nat Lenzo

MBBS (Hons) FRANZCR AFRACMA DMedSc

Radiation Oncologist

Hurstville (Oncology) +1

Dr Brett Sounness

BSc, MBBS, FRANZCR, FAANMS

Nuclear Medicine Physician

Dr Catherine Lucas

BPharm, MBBS, FRACP, FAANMS

Nuclear Medicine Physician

Hurstville (Oncology)

Dr Geoffrey Schembri

MBBS, BSC(MED), DDU, FRACP, FAANMS

Nuclear Medicine Physician

A/Prof Paul Roach

MBBS (HONS), FRACP, FAANMS

Nuclear Medicine Physician

Dr Elizabeth Bernard

MBBS Honours FRACP, FAANMS

Nuclear Medicine Physician

North Shore - Now open

Dr Jeremy Hoang

MBBS (SYD), FRACP, FAANMS, DDU

Nuclear Medicine Physician

Dr Sharon Hain

MBBS, FRACP, BSc, FAANMS

Nuclear Medicine Physician

North Shore - Now open

Dr David Chan

MBBS, FRACP, BSc

Medical Oncologist

North Shore - Now open

Dr Laurence Krieger

MBChB (Hons) FRACP

Medical Oncologist

North Shore - Now open